Epigenetic and biogenetic regulation by polyphenols in prostate cancer in the context of 3P medicine
- PMID: 39991103
- PMCID: PMC11842649
- DOI: 10.1007/s13167-024-00391-3
Epigenetic and biogenetic regulation by polyphenols in prostate cancer in the context of 3P medicine
Abstract
Prostate cancer (PCa) can remain asymptomatic for years, complicating early detection and effective intervention. Predictive, Preventive, and Personalized Medicine (3PM) provides a transformative framework for addressing these challenges by integrating novel biomarkers, targeted prevention, and individualized therapies. Recent studies highlight the pivotal role of dysregulated microRNAs (miRNAs) and epigenetic alterations in cancer progression and metastasis. miRNAs, as non-coding RNAs approximately 22 nucleotides in length, regulate gene expression through translational inhibition or mRNA degradation. Dysregulated miRNAs are linked to the overexpression of oncogenic proteins and suppression of tumor suppressor genes in malignancies. Polyphenols such as curcumin, quercetin, resveratrol, and green tea catechins (EGCG) have demonstrated potential in modulating miRNA expression and reversing aberrant epigenetic modifications. Despite their established anticancer effects, the clinical application of polyphenols in stratified patient groups, particularly in primary and secondary cancer prevention, remains underexplored. Beyond their anti-inflammatory and antioxidant properties, polyphenols modulate early epigenetic and biogenetic events critical for cancer prevention and therapy. By targeting predictive biomarkers and improving therapy response, polyphenols contribute significantly to 3PM by enabling early diagnostics, mitigating risks, and personalizing treatments. This review evaluates current knowledge of polyphenols' impact on miRNAs and epigenetics in PCa and explores their potential applications within the 3PM framework, emphasizing predictive diagnostics, targeted prevention, and personalized treatment strategies.
Keywords: Anti-inflammatory and antioxidant properties; Apoptosis; Cancer progression and metastasis; Curcumin; DNA methylation; Epigenetic regulation; Green tea; MiRNAs; Oncology; Polyphenols; Predictive, Preventive, and Personalized Medicine (3PM / PPPM); Prostate cancer; Quercetin; Resveratrol; Risk mitigation; Therapy response.
© The Author(s), under exclusive licence to European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Conflict of interest statement
Competing interestsThe authors declare no competing interests.
Similar articles
-
Application of ChatGPT-4 to oculomics: a cost-effective osteoporosis risk assessment to enhance management as a proof-of-principles model in 3PM.EPMA J. 2024 Aug 28;15(4):659-676. doi: 10.1007/s13167-024-00378-0. eCollection 2024 Dec. EPMA J. 2024. PMID: 39635018
-
Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management.EPMA J. 2025 Mar 22;16(2):465-503. doi: 10.1007/s13167-025-00403-w. eCollection 2025 Jun. EPMA J. 2025. PMID: 40438490 Review.
-
Polyphenol-Based Nutritional Strategies Combined With Exercise for Brain Function and Glioma Control: Focus on Epigenetic Modifications, Cognitive Function, Learning and Memory Processes.Food Sci Nutr. 2025 Aug 10;13(8):e70758. doi: 10.1002/fsn3.70758. eCollection 2025 Aug. Food Sci Nutr. 2025. PMID: 40792048 Free PMC article. Review.
-
Phenolic compounds and epigenetic mechanisms regulating gene expression: effects on human health.J Physiol Biochem. 2025 Jul 7. doi: 10.1007/s13105-025-01105-7. Online ahead of print. J Physiol Biochem. 2025. PMID: 40624433 Review.
-
The Potential of MicroRNAs as Prostate Cancer Biomarkers.Eur Urol. 2016 Aug;70(2):312-22. doi: 10.1016/j.eururo.2015.12.054. Epub 2016 Jan 22. Eur Urol. 2016. PMID: 26806656 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68:394–424. - PubMed
-
- Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–92. - PubMed
-
- Kuruma H, Egawa S. Words of Wisdom: re: international variation in prostate cancer incidence and mortality rates. Eur Urol. 2013;63:583–4. - PubMed
Publication types
LinkOut - more resources
Full Text Sources